The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber
- 1.2k Downloads
Objective and design
This double-blind cross-over study compared the potential of bilastine, cetirizine, and fexofenadine to relieve the symptoms of allergic rhinitis.
Subjects and methods
Seventy-five allergic volunteers were challenged with grass pollen in the Vienna Challenge Chamber (VCC) on two consecutive days of allergen provocation; 6 h on day 1 and 4 h day 2. Bilastine 20 mg, cetirizine 10 mg, fexofenadine 120 mg, or placebo were taken orally 2 h after the start of provocation on day 1 only. Total nasal symptom scores, the global symptom scores, nasal secretions, and eye symptoms were assessed on both day 1 and day 2.
Results and conclusions
Bilastine had a rapid onset of action, within 1 h, and a long duration of action, greater than 26 h. Cetirizine was similar. Fexofenadine was similar on day 1 but less effective on day 2, indicating a shorter duration of action. Bilastine, like cetirizine and fexofenadine, was safe and well tolerated in this study.
KeywordsBilastine Cetirizine Fexofenadine Allergic rhinitis Vienna Challenge Chamber
The authors thank FAES FARMA, Bilbao, Spain, for financial assistance.
- 1.Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43.CrossRefPubMedGoogle Scholar
- 10.Sologuren A, Valiente R. Relationship of dose to inhibition of wheal and flare for 5 doses bilastine and 10 mg cetirizine. In: Proceedings of the 36th ACCP Annual Meeting, San Francisco, CA, 9–11 September; 2007.Google Scholar
- 11.Audicana MT. A double blind, randomized, dose ranging trial in four parallel groups of 10, 20 and 30 mg bilastine once daily vs placebo in the symptomatic treatment of chronic idiopatic urticaria. In: Proceedings of SEIAC, Santander (Spain); 2007.Google Scholar
- 12.Alison M, Benoit T, Sologuren A. Lack of significant effect of bilastine on ventricular repolarization. A throrough QT/QTc study. In: Proceedings of the EAACI Congress, Barcelona (Spain), 7–11 June; 2008.Google Scholar
- 13.Garcia-Gea C, Martinez-Colomer J, Antonijoan RM, Valiente R, Barbanoj MJ. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol. 2008;28:675–85.CrossRefPubMedGoogle Scholar
- 14.Gonzalo A, Lucero ML, Orjales A. Early identification of the processes involved in bilastine bioavailability in rats. In: Proceedings of 10th European Regional ISSX Meeting, Vienna, Austria, 18–21 May; 2008.Google Scholar
- 15.Horak F, Jäger S. Wiener Provokations-Kammer (Vienna Challenge Chamber): eine neue Methode des Allergenexpositionstests. Wiener klin Wochenschr. 1987;99:509–10.Google Scholar
- 18.Stuebner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit—the Vienna Challenge Chamber (VCC). Curr Med Res Opin. 2004;20:891–902.CrossRefGoogle Scholar
- 21.Horak F, Stübner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 2002;109:956–61.CrossRefPubMedGoogle Scholar